Caplin Point Laboratories Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/u0muiol7jvzz6ltbs0sddbz2.pdf

Key Takeaways


The Own-Label Pivot: Caplin Steriles Strategy Shift

Vivek Partheeban: "We should remember that we took a conscious call as a company that we are going to be launching a label of our own in the U.S., right? So when that be the case, at least almost around eight to nine months ago, we stopped doing these exclusive deals where we take on a large milestone payment upfront."

U.S. Business: Approvals, Targets & Pipeline


Latin America: The Next Growth Frontier

C.C. Paarthipan: "See, until now, we have been competing with companies of our size. Now we are in the big boys playground. We need to position ourselves in a unique place that alone can take us actually to the next orbit."

Margins & Cost Structure


Pipeline: Complex Products & New Capabilities


Geopolitics, Competition & Positioning

C.C. Paarthipan: "Business being disrupted fast and it's time for us to be on the winning side, winning side of the disruption, I mean."

Guidance & Commitments

CommitmentSpecificsTimeline
Caplin Steriles own-label launches~20 products launched (from 11 currently)Before end of FY25
Caplin Steriles own-label launches~50 products launchedBefore end of next year
All 28 approved products launchedAll 28 launched in U.S.Within coming few weeks
FDA approvals for products under reviewAll 13 ANDAs under review approvedWithin coming 12 months
U.S. revenue target$100 million overallFY27-FY28
Onco injectable & API factoriesCommence commercial productionApril or May
OSD and Onco API facilitiesCompletedOne or two years from now
Chilean businessStart consistentlyFrom July
Mexican businessReal growth to startMaybe one year from now
Four high-tech productsCommercialization (outer limit)24 to 30 months
Latin America businessAt least doubleNext five years
Caplin Steriles own-label vs B2B mixOwn-label larger than B2BNext 3-5 years
Margin improvementDo better than beforeAfter 3-3.5 years

Key Metrics

MetricQ3 FY25
Total revenue growth16.7% YoY
LatAm business revenue growth (parent)14% YoY
U.S. business revenue growth23% YoY
Gross margin60.4%, second highest; last quarter was 60.9%
EBITDA margin36.9%
PBT margin33.8%
PAT margin26.7%
COGS as a percentage of revenue40%, down from 48% in FY19-20
Operating expenses as a percentage of revenue25% to 26%
Caplin Steriles revenue₹87.8 crores
Caplin Steriles EBITDA₹24 crores
Oncology business turnover₹34 crores, turned positive in first full year of operations
Caplin Steriles USA (CSU) own-label revenue$0.5 million, within first couple of months since November launch
ANDA approvals under Caplin's name28 approvals
Products under review with FDA13 products
Products launched under Caplin Steriles own label11 products so far
Effective tax rate (consolidated)20%
Free cash reserves₹1,081 crores
Liquid assets₹2,042 crores